Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis.

Prentice KJ, Wendell SG, Liu Y, Eversley JA, Salvatore SR, Mohan H, Brandt SL, Adams AC, Serena Wang X, Wei D, FitzGerald GA, Durham TB, Hammond CD, Sloop KW, Skarke C, Schopfer FJ, Wheeler MB.

EBioMedicine. 2018 Jan;27:200-213. doi: 10.1016/j.ebiom.2017.12.019. Epub 2017 Dec 19.

2.

A Pilot Characterization of the Human Chronobiome.

Skarke C, Lahens NF, Rhoades SD, Campbell A, Bittinger K, Bailey A, Hoffmann C, Olson RS, Chen L, Yang G, Price TS, Moore JH, Bushman FD, Greene CS, Grant GR, Weljie AM, FitzGerald GA.

Sci Rep. 2017 Dec 7;7(1):17141. doi: 10.1038/s41598-017-17362-6.

3.

Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury.

Desai BN, Singhal G, Watanabe M, Stevanovic D, Lundasen T, Fisher FM, Mather ML, Vardeh HG, Douris N, Adams AC, Nasser IA, FitzGerald GA, Flier JS, Skarke C, Maratos-Flier E.

Mol Metab. 2017 Nov;6(11):1395-1406. doi: 10.1016/j.molmet.2017.08.004. Epub 2017 Aug 19.

4.

Molecular clocks and the human condition: approaching their characterization in human physiology and disease.

Fitzgerald GA, Yang G, Paschos GK, Liang X, Skarke C.

Diabetes Obes Metab. 2015 Sep;17 Suppl 1:139-42. doi: 10.1111/dom.12526. Review.

5.

Bioactive products formed in humans from fish oils.

Skarke C, Alamuddin N, Lawson JA, Li X, Ferguson JF, Reilly MP, FitzGerald GA.

J Lipid Res. 2015 Sep;56(9):1808-20. doi: 10.1194/jlr.M060392. Epub 2015 Jul 15.

6.

Selective COX-2 inhibitors suppress prostacyclin.

Skarke C, FitzGerald GA.

Clin Ther. 2014 Dec 1;36(12):2120-2121. doi: 10.1016/j.clinthera.2014.09.024. Epub 2014 Oct 23. No abstract available.

PMID:
25450471
7.
8.

Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia.

Lötsch J, Skarke C, Darimont J, Zimmermann M, Bräutigam L, Geisslinger G, Ultsch A, Oertel BG.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Oct;386(10):865-73. doi: 10.1007/s00210-013-0889-5. Epub 2013 Jun 18.

PMID:
23775505
9.

Myrtucommulone from Myrtus communis: metabolism, permeability, and systemic exposure in rats.

Gerbeth K, Hüsch J, Meins J, Rossi A, Sautebin L, Wiechmann K, Werz O, Skarke C, Barrett JS, Schubert-Zsilavecz M, Abdel-Tawab M.

Planta Med. 2012 Dec;78(18):1932-8. doi: 10.1055/s-0032-1327881. Epub 2012 Nov 13.

PMID:
23150076
10.

Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome(®)) of Boswellia extract.

Hüsch J, Bohnet J, Fricker G, Skarke C, Artaria C, Appendino G, Schubert-Zsilavecz M, Abdel-Tawab M.

Fitoterapia. 2013 Jan;84:89-98. doi: 10.1016/j.fitote.2012.10.002. Epub 2012 Oct 23.

11.

Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.

Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA.

Clin Pharmacol Ther. 2012 Jun;91(6):986-93. doi: 10.1038/clpt.2012.3. Epub 2012 Jan 25.

12.

Increased bioavailability of 11-keto-β-boswellic acid following single oral dose frankincense extract administration after a standardized meal in healthy male volunteers: modeling and simulation considerations for evaluating drug exposures.

Skarke C, Kuczka K, Tausch L, Werz O, Rossmanith T, Barrett JS, Harder S, Holtmeier W, Schwarz JA.

J Clin Pharmacol. 2012 Oct;52(10):1592-600. Epub 2011 Dec 13. No abstract available.

PMID:
22167571
13.

Training translators for smart drug discovery.

Skarke C, FitzGerald GA.

Sci Transl Med. 2010 Apr 7;2(26):26cm12. doi: 10.1126/scitranslmed.3000890.

PMID:
20375362
14.

Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense.

Tausch L, Henkel A, Siemoneit U, Poeckel D, Kather N, Franke L, Hofmann B, Schneider G, Angioni C, Geisslinger G, Skarke C, Holtmeier W, Beckhaus T, Karas M, Jauch J, Werz O.

J Immunol. 2009 Sep 1;183(5):3433-42. doi: 10.4049/jimmunol.0803574. Epub 2009 Jul 31.

15.

On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance.

Siemoneit U, Pergola C, Jazzar B, Northoff H, Skarke C, Jauch J, Werz O.

Eur J Pharmacol. 2009 Mar 15;606(1-3):246-54. doi: 10.1016/j.ejphar.2009.01.044. Epub 2009 Feb 5.

PMID:
19374837
16.

Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance.

Skarke C, Schuss P, Kirchhof A, Doehring A, Geisslinger G, Lötsch J.

Pharmacogenomics. 2007 Dec;8(12):1643-60.

PMID:
18085997
17.

Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers.

Graff J, Skarke C, Klinkhardt U, Watzer B, Harder S, Seyberth H, Geisslinger G, Nüsing RM.

J Thromb Haemost. 2007 Dec;5(12):2376-85. Epub 2007 Oct 3.

18.

The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production.

Skarke C, Reus M, Schmidt R, Grundei I, Schuss P, Geisslinger G, Lötsch J.

Clin Pharmacol Ther. 2006 Dec;80(6):621-32.

PMID:
17178263
19.

Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.

Rohrbacher M, Kirchhof A, Skarke C, Geisslinger G, Lötsch J.

Pharmacogenomics. 2006 Mar;7(2):167-76.

PMID:
16515396
20.

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.

Lötsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmöller J, Geisslinger G.

Clin Pharmacol Ther. 2006 Jan;79(1):72-89.

PMID:
16413243
21.

Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites.

Lötsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M, Geisslinger G.

Clin Pharmacol Ther. 2006 Jan;79(1):35-48.

PMID:
16413240
22.

Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing.

Skarke C, Kirchhof A, Geisslinger G, Lötsch J.

Eur J Clin Pharmacol. 2005 Dec;61(12):887-92. Epub 2005 Nov 24. Review.

PMID:
16307269
23.

The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression.

Lötsch J, Skarke C, Schneider A, Hummel T, Geisslinger G.

Clin Pharmacol Ther. 2005 Sep;78(3):278-87.

PMID:
16153398
24.

Is morphine-3-glucuronide of therapeutic relevance?

Skarke C, Geisslinger G, Lötsch J.

Pain. 2005 Aug;116(3):177-80. Review. No abstract available.

PMID:
15982815
25.

[Fundamental principles of clinical trials].

Skarke C, Geisslinger G.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Apr;48(4):401-7. German.

PMID:
15830250
26.

Comparison of two screening methods for in-house genotyping in clinical pharmacology units.

Darimont J, Grösch S, Skarke C, Geisslinger G, Lötsch J.

Int J Clin Pharmacol Ther. 2005 Jan;43(1):17-22.

PMID:
15704610
27.

Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans.

Skarke C, Langer M, Jarrar M, Schmidt H, Geisslinger G, Lötsch J.

Anesthesiology. 2004 Dec;101(6):1394-9.

PMID:
15564947
28.

Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Lötsch J, Skarke C, Liefhold J, Geisslinger G.

Clin Pharmacokinet. 2004;43(14):983-1013. Review.

PMID:
15530129
29.

Single-step identification of all length polymorphisms in the UGT1A1 gene promoter.

Skarke C, Grösch S, Geisslinger G, Lötsch J.

Int J Clin Pharmacol Ther. 2004 Mar;42(3):133-8.

PMID:
15049432
30.

Comprehensive mu-opioid-receptor genotyping by pyrosequencing.

Skarke C, Kirchhof A, Geisslinger G, Lötsch J.

Clin Chem. 2004 Mar;50(3):640-4. No abstract available.

31.

Olfactory function in mild cognitive impairment and Alzheimer's disease: an investigation using psychophysical and electrophysiological techniques.

Peters JM, Hummel T, Kratzsch T, Lötsch J, Skarke C, Frölich L.

Am J Psychiatry. 2003 Nov;160(11):1995-2002.

PMID:
14594747
32.

Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers.

Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lötsch J.

Pharmacogenetics. 2003 Nov;13(11):651-60.

PMID:
14583678
33.

Simultaneous screening for three mutations in the ABCB1 gene.

Lötsch J, Skarke C, Geisslinger G.

Genomics. 2003 Nov;82(5):503-10.

PMID:
14559207
34.

Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine.

Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lötsch J.

Clin Pharmacol Ther. 2003 Oct;74(4):303-11.

PMID:
14534517
35.

Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome.

Skarke C, Schmidt H, Geisslinger G, Darimont J, Lötsch J.

Br J Clin Pharmacol. 2003 Aug;56(2):228-31.

36.

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers.

Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J.

Clin Pharmacol Ther. 2003 Jan;73(1):107-21.

PMID:
12545149
37.

Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?

Lötsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C, Geisslinger G.

Anesthesiology. 2002 Oct;97(4):814-9.

PMID:
12357145
38.

Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers.

Lötsch J, Skarke C, Schmidt H, Liefhold J, Geisslinger G.

Clin Pharmacol Ther. 2002 Aug;72(2):151-62.

PMID:
12189362
39.

The influence of inhibition of probenecid sensitive transporters on the central nervous system (CNS) uptake and the antinociceptive activity of morphine-6-glucuronide in rats.

Lötsch J, Schmidt R, Vetter G, Schmidt H, Skarke C, Niederberger E, Geisslinger G, Tegeder I.

Neurosci Lett. 2002 Aug 30;329(2):145-8.

PMID:
12165398
40.

Drug interactions with patient-controlled analgesia.

Lotsch J, Skarke C, Tegeder I, Geisslinger G.

Clin Pharmacokinet. 2002;41(1):31-57. Review.

PMID:
11825096
41.

The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.

Lötsch J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger G.

Pharmacogenetics. 2002 Jan;12(1):3-9.

PMID:
11773859
42.

The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers.

Lötsch J, Skarke C, Schmidt H, Grösch S, Geisslinger G.

Anesthesiology. 2001 Dec;95(6):1329-38.

PMID:
11748388
43.

A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene.

Grösch S, Niederberger E, Lötsch J, Skarke C, Geisslinger G.

Br J Clin Pharmacol. 2001 Dec;52(6):711-4.

44.

Effects of the opioid remifentanil on olfactory function in healthy volunteers.

Lötsch J, Darimont J, Skarke C, Zimmermann M, Hummel T, Geisslinger G.

Life Sci. 2001 Sep 28;69(19):2279-85.

PMID:
11669470
45.

[Hypertensive microangiopathy].

Skarke C, Stellwaag M.

Dtsch Med Wochenschr. 2000 Apr 20;125 Suppl 1:S14-5. German. No abstract available.

PMID:
10819000
46.

Differential expression of cell adhesion molecules in inflamed appendix: correlation with clinical stage.

Bittinger F, Brochhausen C, Köhler H, Lehr HA, Otto M, Skarke C, Walgenbach S, Kirkpatrick CJ.

J Pathol. 1998 Dec;186(4):422-8.

PMID:
10209493
47.

Remodeling of peritoneal-like structures by mesothelial cells: its role in peritoneal healing.

Bittinger F, Schepp C, Brochhausen C, Lehr HA, Otto M, Köhler H, Skarke C, Walgenbach S, Kirkpatrick CJ.

J Surg Res. 1999 Mar;82(1):28-33.

PMID:
10068522
48.

Reconstruction of peritoneal-like structure in three-dimensional collagen gel matrix culture.

Bittinger F, Brochhausen C, Skarke C, Köhler H, Kirkpatrick CJ.

Exp Cell Res. 1997 Oct 10;236(1):155-60.

PMID:
9344595
49.

PECAM-1 expression in human mesothelial cells: an in vitro study.

Bittinger F, Klein CL, Skarke C, Brochhausen C, Walgenbach S, Röhrig O, Köhler H, Kirkpatrick CJ.

Pathobiology. 1996;64(6):320-7.

PMID:
9159026
50.

Effects of cytokines on the expression of cell adhesion molecules by cultured human omental mesothelial cells.

Klein CL, Bittinger F, Skarke CC, Wagner M, Köhler H, Walgenbach S, Kirkpatrick CJ.

Pathobiology. 1995;63(4):204-12.

PMID:
8866792

Supplemental Content

Loading ...
Support Center